장기간 또는 반복 노출되면 장기(또는, 영향을 받은 알려진 모든 장기를 명시)에 손상을 일으킬 수 있음
특정 표적장기 독성 - 반복 노출
구분 2
경고
P260, P314, P501
H400
수생생물에 매우 유독함
수생 환경유해성 물질 - 급성
구분 1
경고
P273, P391, P501
H410
장기적 영향에 의해 수생생물에 매우 유독함
수생 환경유해성 물질 - 만성
구분 1
경고
P273, P391, P501
예방조치문구:
P260
분진·흄·가스·미스트·증기·...·스프레이를 흡입하지 마시오.
P261
분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.
P271
옥외 또는 환기가 잘 되는 곳에서만 취급하시오.
P273
환경으로 배출하지 마시오.
P304+P340
흡입하면 신선한 공기가 있는 곳으로 옮기고 호흡하기 쉬운 자세로 안정을 취하시오.
P312
불편함을 느끼면 의료기관(의사)의 진찰을 받으시오.
P314
불편함을 느끼면 의학적인 조치·조언을 구하시오.
P391
누출물을 모으시오.
P403+P233
용기는 환기가 잘 되는 곳에 단단히 밀폐하여 저장하시오.
P405
밀봉하여 저장하시오.
P501
...에 내용물 / 용기를 폐기 하시오.
Suvorexant C화학적 특성, 용도, 생산
개요
Suvorexant, a dual orexin receptor antagonist marketed under
the trade name Belsomra®, discovered and developed by Merck
for the treatment of insomnia, was approved by the US FDA in
August 2014 and became available in Japan in November of the
same year. The drug’s mechanism of action operates through
the competitive blockade of wake-promoting neuropeptides orexin
A and orexin B toward receptors orexin receptor type 1 and orexin
receptor type 2, which are believed to modulate sleep-wake
cycles.
용도
Suvorexant (MK-4305) is a dual (non-selective) orexin receptor antagonist in development by Merck & Co. for the treatment of insomnia. It works by turning off wakefulness rather than by inducing sleep. Users of higher doses had an increased rate of suicidal ideation.
정의
ChEBI: Suvorexant is an aromatic amide obtained by formal condensation of the carboxy group of 5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid with the secondary amino group of 5-chloro-2-[(5R)-5-methyl-1,4-diazepan-1-yl]-1,3-benzoxazole. An orexin receptor antagonist used for the management of insomnia. It has a role as a central nervous system depressant and an orexin receptor antagonist. It is a member of 1,3-benzoxazoles, a member of triazoles, a diazepine, an aromatic amide and an organochlorine compound.
생물학적 활성
Suvorexant is a dual orexin receptor (OXR) antagonist that blocks both OX1R and OX2R (Kis = 1.2 and 0.60 nM, respectively). It reduces locomotor activity and promotes sleep by inhibiting the binding of orexin A and B. In rats, suvorexant decreases self-administration of, and conditioned place preference for, cocaine ( | 16186 | ISO60176). It also decreases dopamine levels in the rat ventral striatum following a cocaine-induced increase. Formulations containing suvorexant are used in the treatment of insomnia. Suvorexant is regulated as a Schedule IV compound in the United States. This compound is also available as an analytical reference standard.
신진 대사
Suvorexant is primarily metabolized by cytochrome-P450 3A4 enzyme (CYP3A4) with a minor contribution from CYP2C19. Major circulating metabolites are suvorexant and a hydroxy-suvorexant metabolite, which is not expected to be pharmacologically active. There is potential for drug-drug interactions with drugs that inhibit or induce CYP3A4 activity.